Addendum

Ublituximab (multiple sclerosis) – Addendum to Project A24-13

Status
Status: Commission completed
Project no.
A24-68
Last updated

Report documents

  1. Addendum

    Ublituximab (multiple sclerosis) – Addendum to Project A24-13

    published on
    Document type
    PDF document, 3 MB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-68_en

Dossier assessment

Indication:

Adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

Result of dossier assessment:
  • Men who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: proof of considerable added benefit
  • Women who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: added benefit not proven
  • Patients who have not yet received disease-modifying therapy and show evidence of a severe course of disease and adults who show an active course of disease despite treatment with a disease-modifying therapy: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

01-08-2024 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A24-68
Commission
Commission awarded on 11.06.2024 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A24-68_en

Connected Projects

  1. Dossier assessment

    Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-13
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form